CanSino Biologics Inc. introduced that the New Drug Application (NDA) for its Tetanus, Reduced Diphtheria, and Pertussis (Acellular, Five Components) Combined Vaccine, Adsorbed, has been accepted by China’s National Medical Products Administration. This vaccine, often called the Td5cp Adolescent and Adult, is designed as a booster for people aged six years and above and was granted Priority Review standing in May 2026.
The acceptance of the NDA signifies a vital step in CanSinoBIO’s efforts to develop its pertussis-containing vaccine portfolio. If authorized, the Td5cp Adolescent and Adult vaccine is predicted to enhance CanSinoBIO’s just lately authorized next-generation three-component DTaP vaccine, Tripecia, additional strengthening the corporate’s place within the vaccine market throughout numerous age teams.
Pertussis, a extremely contagious respiratory illness, has seen a resurgence globally, with reported instances in China exceeding 470,000 in 2024. This represents a major improve in comparison with the earlier yr, highlighting the rising significance of booster immunization throughout adolescence and maturity. Despite the rising instances, China has lacked a devoted booster immunization product for these aged six and above till now.
CanSinoBIO’s Tripecia, a Diphtheria, Tetanus, and Pertussis (Acellular, Three Components) Combined Vaccine for infants, was authorized for advertising earlier this yr. The Td5cp Adolescent and Adult vaccine builds on this success by together with two further pertussis antigens, FIM2 and FIM3, guaranteeing steady product high quality and consistency.
The development of the Td5cp Adolescent and Adult vaccine aligns with China’s “15th Five-Year Plan for Disease Prevention and Control,” which emphasizes a life-course immunization technique. This plan goals to supply complete immunization safety for all age teams, supporting the event of progressive vaccine options.
From a enterprise perspective, the acceptance of the NDA for the Td5cp Adolescent and Adult vaccine marks an necessary milestone in CanSinoBIO’s vaccine analysis and growth efforts. It additionally strengthens market expectations for the corporate’s pipeline of mixture vaccine candidates and lays the groundwork for medium- to long-term efficiency development.